Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

Fig. 1

Effects of selinexor on cell proliferation in vitro. Twenty-six breast cancer cell lines representing varying hormone receptor status were treated with selinexor at 10 concentrations based on a fivefold dilution series (range 0 to 100 μM). Cell growth was measured after 72 hours of treatment using the sulforhodamine B assay, and half-maximal inhibitory concentration (IC 50 ) was then calculated using isobologram curves, with an overall median IC50 of 66 nM (range 11 to >1000 nM). Sensitivity was defined as IC50 < 1000 nM, a physiologically achievable dose based on previous phase I studies. TP53, PTEN, PIK3CA, and Ras/Raf status is shown. Green circle wild type, red circle mutation/deletion or frameshift. ER estrogen receptor, HER2 human epidermal growth factor receptor, TNBC triple-negative breast cancer

Back to article page